[1]张洪瑞,陈虎,朱靖,等.新型碘油制剂及肝癌介入治疗研究进展[J].中国材料进展,2022,41(09):742-748.[doi:10.7502/j.issn.1674-3962.202109037]
 ZHANG Hongrui,CHEN Hu,ZHU Jing,et al.Research Progress of Lipiodol Emulsion in Transarterial Interventional Embolization for Hepatocellular Carcinoma[J].MATERIALS CHINA,2022,41(09):742-748.[doi:10.7502/j.issn.1674-3962.202109037]
点击复制

新型碘油制剂及肝癌介入治疗研究进展()
分享到:

中国材料进展[ISSN:1674-3962/CN:61-1473/TG]

卷:
41
期数:
2022年第09期
页码:
742-748
栏目:
出版日期:
2022-09-30

文章信息/Info

Title:
Research Progress of Lipiodol Emulsion in Transarterial Interventional Embolization for Hepatocellular Carcinoma
文章编号:
1674-3962(2022)09-0742-07
作者:
张洪瑞1陈虎1朱靖1毛景松2刘刚1
(1.厦门大学公共卫生学院 分子影像暨转化医学研究中心,福建 厦门 361102)(2.厦门大学附属翔安医院 介入科,福建 厦门 361102)
Author(s):
ZHANG Hongrui1 CHEN Hu1 ZHU Jing1 MAO Jingsong2 LIU Gang1
(1. Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China) (2. Department of Intervention, Xiang’an Hospital, Xiamen University, Xiamen 361102, China)
关键词:
碘油乳剂稳定性肝细胞癌介入治疗
Keywords:
lipiodol emulsion stability hepatocellular carcinoma interventional therapy
分类号:
R815
DOI:
10.7502/j.issn.1674-3962.202109037
文献标志码:
A
摘要:
碘油因其特异性滞留于肝细胞癌组织的性质已成为肝细胞癌(hepatocellular carcinoma, HCC)患者介入治疗最常用的栓塞剂。以碘油为载体,混合各类抗肿瘤药物制备成的新型碘油药物乳剂用于中晚期肝癌介入栓塞治疗的策略已得到临床广泛研究应用。但是不同碘油药物乳剂的适应症和疗效存在较大差异,并且目前碘油乳剂普遍存在着稳定性能不佳的难题,限制了碘油乳剂在HCC介入治疗中的发展和应用。科学选用碘油药物乳剂及增加碘油乳剂的稳定性将是提高中晚期肝癌介入栓塞治疗疗效的关键。对碘油联合药物的种类以及增加碘油乳剂稳定性的相关方法进行综述,为临床实践提供参考。
Abstract:
Transarterial interventional embolization is one of the commonly used methods that are not suitable for surgical resection of patients with hepatocellular carcinoma. Lipiodol has become the most commonly used embolization agent for interventional therapy of hepatocellular carcinoma (HCC) due to its specific retention in HCC tissues. Using lipiodol as a carrier and mixing various antitumor drugs to prepare lipiodol drug emulsions for interventional embolization of advanced HCC strategies has been widely studied and applied in clinical practice. However, the application scenarios and curative effects of different lipiodol drug emulsions are quite different, and the current lipiodol emulsion generally has the problem of poor stability, which limits the development and application of lipiodol emulsion in interventional treatment of HCC. The scientific selection of lipiodol emulsion and increasing the stability of lipiodol emulsion will be the key to improve the curative effect of interventional embolization of advanced HCC.This article will review the types of lipiodol combined drugs and the related methods to increase the stability of lipiodol emulsion, so as to provide reference for clinical practice.

备注/Memo

备注/Memo:
收稿日期:2021-09-26 修回日期:2022-08-10 基金项目:科技部国家重点研发计划项目(2017YFA0205201);国家自然科学基金杰出青年基金项目(81925019)第一作者:张洪瑞,男,1995年生,硕士研究生通讯作者:刘刚,男,1979年生,教授,博士生导师, Email:gangliucmitm@xmu.edu.cn 毛景松,男,1979年生,副主任医师,硕士生导师, Email:maojingsong163@163.com
更新日期/Last Update: 2022-08-22